Galecto (NASDAQ:GLTO – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.16, Zacks reports.
Galecto Stock Performance
NASDAQ:GLTO opened at $0.54 on Wednesday. The firm’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.64. The firm has a market cap of $14.68 million, a price-to-earnings ratio of -0.47 and a beta of 1.17. Galecto has a one year low of $0.46 and a one year high of $2.45.
Analyst Ratings Changes
Separately, Oppenheimer decreased their target price on Galecto from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Monday, June 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.33.
Galecto Company Profile
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Featured Articles
- Five stocks we like better than Galecto
- Investing in Large Cap Stocks: Best Large Cap Stocks to Buy and How to Research
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- What Does a Stock Split Mean?
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- How to Invest in the Best Canadian Stocks
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.